Evolution and etiopathogenesis of bisphosphonates induced osteonecrosis of the jaw

North American Journal of Medical Sciences

Volumn 5, Issue 4, 2013, Pages 260-265

  Kumar, Vijay ^a   Sinha, Raman Kant ^b  

^a Department of Oral and Maxillofacial Surgery   (India)

^b Sarjug Dental College and Hospital   (India)

Author keywords

Bisphosphonates; Bisphosphonates induced osteonecrosis of the jaw; Evolution and BPs induced ONJ; Pathogenesis of BPs induced ONJ

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; IBANDRONIC ACID; INTERLEUKIN 6; PAMIDRONIC ACID; PARATHYROID HORMONE; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ANTIANGIOGENIC ACTIVITY; AVASCULAR NECROSIS; BONE CANCER; BONE REMODELING; CALCIFICATION; DISEASE COURSE; DRUG EXPOSURE; EYE DISEASE; FEMUR FRACTURE; GASTROINTESTINAL DISEASE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPOCALCEMIA; IMMUNE RESPONSE; JAW OSTEONECROSIS; KIDNEY TRANSPLANTATION; MUSCULOSKELETAL PAIN; NEPHROTOXICITY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PATHOGENICITY; REVIEW; SIDE EFFECT;

EID: 84876078833     PISSN: 22501541     EISSN: 19472714     Source Type: Journal    
DOI: 10.4103/1947-2714.110429     Document Type: Review

References (31)

1. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:30-4.
2. Russell RG. Bisphosphonates: From bench to bed side. Ann NY Acad Sci 2006;1068:367-401.
3. Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens) 2009;8:96-110.
4. Bertoldo F, Santini D, LoCascio V. Bisphosphonates and osteomyelitis of the jaw: A pathogenic puzzle. Nat Clin Pract Oncol 2007;4:711-21.
5. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the jaw-2009 Update. Approved by t h e B o a r d o f T r u s t e e s J a n u a r y 2 0 0 9. A c c e s s e d Month Date, Year, at, http://www.aaoms.org/docs/position_paper/bronj_updatepdfAAOMSPositionPaper onBisphosphonates-RelatedOsteonecrosisoftheJaw-2009 Update [Last accessed date 22 Nov. 2012].
6. Suzuki BJ, Klemes AB. Osteoporosis and Osteonecrosis of the Jaw. American Dental Hygienists Association. Special Supplementary Issue-MAR 2008. ADHA. Supplement to Access-March 2008.
7. Vincenzi B, Napolitano A, Zoccoli A, Iuliani M, Pantano F, Papapietro N, et al. Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw. J Hematol Oncol 2012;5:56.
8. Compston JE, Bilezikian JP. Bisphosphonate therapy for osteoporosis: The long and short of it. J Bone Miner Res 2012; 27:240-2.
9. NSW Health Guide line. Prevention of osteonecrosis of the jaw (ONJ) on patients with Bisphosphonates therapy. GL 2010_010 July 2010. Accessed Month Date, Year, at, http://www.health.nsw.gov.au/policies/gl/2010/pdf/GL2010_010.pdf [Last accessed date 16 Sep. 2012].
10. Lam DK, Sándor GK, Holmes HI, Evans AW, Clokie CM. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc 2007;73:417-22.
11. Andriani A, Petrucci MT, Caravita T, Montanaro M, Villivà N, Levi A, et al. Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom's macro globulinemia: A retrospective multicentric study. Blood Cancer J 2012;2:e62.
12. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7.
13. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
14. Woo SB, Hellstein JW, Kalmar JR. Narrative corrected review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61.
15. McLeod NM, Brennan PA, Ruggiero SL. Bisphosphonate osteonecrosis of the jaw: A historical and contemporary review. Surgeon 2012;10:36-42.
16. Popovic KS, Kocar M. Imaging findings in bisphosphonateinduced osteonecrosis of the jaws. Radiol Oncol 2010;44:215-9.
17. Russell RG. Bisphosphonates: Mode of action and pharmacology. Pediatrics 2007; 119(Suppl 2): S150-62.
18. Hewitt C, Farah CS. Bisphosphonate-related osteonecrosis of the jaws: A comprehensive review. J Oral Pathol Med 2007; 36:319-28.
19. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: Current status. Clin Cancer Res 2006;12:6222s-30.
20. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17:897-907.
21. Kim YG, Lee YD, Kwon YD, Suh JH, Jeen SM. Study on bisphosphonates-related osteonecrosis of the jaw (BRONJ): Case report and literature review. J Korean Assoc Oral Maxillofac Surg 2010;36:291-302.
22. Borgioli A, Viviani C, Duvina M, Brancato L, Spinelli G, Brandi ML, et al. Biphosphonates-related osteonecrosis of the jaw: Clinical and physio-pathological considerations. The Clin Risk Manag 2009; 5:217-27.
23. Ardine M, Generali D, Donadio M, Bonardi S, Scoletta M, Vandone AM, et al. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol 2006;17:1336-7.
24. Reid IR. Osteonecrosis of the jaw: Who gets it, and why? Bone 2009;44:4-10.
25. Ji X, Pushalkar S, Li Y, Glickman R, Fleisher K, Saxena D. Antibiotic effects on bacterial profile in osteonecrosis of the jaw. Oral Dis 2012;18:85-95.
26. Sedghizadeh PP, Yooseph S, Fadrosh DW, Zeigler-Allen L, Thiagarajan M, Salek H, et al. Metagenomic investigation of microbes and viruses in patients with jaw osteonecrosis associated with bisphosphonate therapy. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;114:764-70.
27. Pazianas M. Osteonecrosis of the jaw and the role of macrophages. J Nat Cancer Inst 2011;103:232-40.
28. Gupta J, Gill AS, Sikri P. Evaluation of the relative efficacy of an alloplast used alone and in conjunction with an osteoclast inhibitor in the treatment of human periodontal infra bony defects: A clinical and radiological study. Indian J Dent Res 2011;22:225-31.
29. Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 2007;92:1172-5.
30. Ewing GW, Parvez SH. The multi-systemic nature of diabetes mellitus: Genotype or phenotype? N Am J Med Sci 2010;2:444-56.
31. Park W, Lee SH, Park KR, Rho SH, Chung WY, Kim HJ. Characteristics of bisphosphonate-related osteonecrosis of the jaw after kidney transplantation. J Craniofac Surg 2012;23:e510-4.